Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis [PDF]
Journal of Ophthalmic Inflammation and InfectionObjective To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI ...
Battuya Ganbold +21 more
doaj +4 more sources
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema [PDF]
BMC Ophthalmology, 2019 Background Diabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity ...
Verónica Castro-Navarro +5 more
doaj +4 more sources
Intravitreal Injection of Ozurdex® Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up [PDF]
Ophthalmology and Eye Diseases, 2016 Aim To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). Methods A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with ...
Fernanda Pacella +8 more
doaj +5 more sources
Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex ® in patients with uveitic cystoid macular edema [PDF]
Indian Journal of Ophthalmology, 2015 Purpose: To correlate the structural and functional changes following intravitreal injection of dexamethasone 0.7 mg (Ozurdex ® ) implant in patients with recalcitrant uveitic cystoid macular edema (CME).
Pooja Bansal +4 more
doaj +4 more sources
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients [PDF]
BMC Ophthalmology, 2018 Background To assess corneal endothelial cell changes after intravitreal dexamethasone (DEX) implant (Ozurdex®) injection in patients with macular edema secondary to retinal vein occlusion (RVO).
Hatice Ayhan Güler +6 more
doaj +3 more sources
Active removal of anterior segment-migrated dexamethasone implant (Ozurdex®). [PDF]
GMS Ophthalmol Cases, 2022 Background: Ozurdex® (Allergan plc., Dublin, Ireland) is an intravitreal sustained-release dexamethasone (DEX) implant. The implant has been reported to migrate into the anterior chamber, potentially causing corneal decompensation.
Depla JAM, Veckeneer M, Bleyen I.
europepmc +3 more sources
Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report a case of peripheral ulcerative keratitis (PUK) successfully treated with subconjunctival dexamethasone implant (Ozurdex®) injection. Observations: An 82-year-old female presented with PUK in the right eye.
Hashem H. Ghoraba +6 more
doaj +3 more sources
Oman Journal of Ophthalmology, 2012 Context: Dexamethasone Posterior-Segment Drug Delivery System is a novel, biodegradable, sustained-release drug delivery system (OZURDEX® ) for treatment of macular edema following retinal vein occlusion and posterior uveitis. However, its potential role
Pukhraj Rishi +3 more
doaj +2 more sources
Hole-in-one: simple non-surgical technique for the management of anterior chamber migrated Ozurdex® implant. [PDF]
GMS Ophthalmol Cases, 2020 Introduction: The migration of a dexamethasone implant to the anterior chamber is a vision-threatening complication which can happen in non-compartmentalized eyes treated with this device.
Rivera-Pérez de Rada P +7 more
europepmc +4 more sources
Revista Brasileira de Oftalmologia, 2021 This report aims to describe the effectiveness of a unilateral intravitreal dexamethasone implant (Ozurdex®) used for the treatment of cystoid macular edema in a patient with recurrent intermediate uveitis.
Bruno Boalento dos Santos +3 more
doaj +2 more sources